The current clinical evidence suggests that sorafenib administration can provide benefits in AML patients harboring FLT3-ITD mutation (Röllig et al. 2015; Deol et al. 2016; Battipaglia et al. 2017). Here, FLT3 is linked to acute myeloid leukemia.